Treatment
ICER, a nonprofit that conducts independent reviews on clinical effectiveness and value of treatments, found Dupixent to be a “high value” drug for adults with atopic dermatitis.
In March, the FDA approved Dupixent, the first biologic medication for adults with moderate to severe atopic dermatitis. Clinical research investigator Dr Paul Yamauchi answers questions about the new medication.
Internet renowned pediatric dermatologist Dr. Richard Aron uses a unique compounded topical to treat eczema patients.
How an ancient treatment helped little Elina Tell us about your daughter Elina and her experience with eczema. Elina’s eczema began when she was 2 months old. By the time she was 4, her itching intensified to the point that she would wake up every single night scratching and was unable to go back to sleep. […]
The U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD).
Our skin is covered in a web of billions of tiny organisms including bacteria, viruses and fungi. This web is called the skin microbiome and when healthy, helps our bodies function properly inside and out. Researchers have long known that people with atopic dermatitis (AD) have different skin biology than those who do not have […]
Each year, thousands of doctors, scientists, students, industry and patient advocacy groups like National Eczema Association, gather to hear the latest research and standards of medical care in dermatology at the American Academy of Dermatology (AAD) Annual Meeting. Photo Credit Dermatology World Atopic dermatitis is a hot field of study. Here’s some highlights from this […]
There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to severe AD. As more […]
Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are already being used to […]
What is atopic dermatitis (AD)? AD is a severe form of eczema, which is an umbrella term used to describe a group of conditions that result in itchy, red, and irritated skin. It is a chronic, inflammatory disease that results in red, itchy patches on the skin that can crack and weep. AD falls into […]
Copyright 2002-2017
National Eczema Association
4460 Redwood Highway, Ste. 16-D
San Rafael, CA 94903